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ABSTRACT
Objectives: We aimed to evaluate and compare the clinical and pathological features, diagnosis, treatment, and prognosis 
of uterine papillary serous carcinoma (UPSC) and clear-cell carcinoma (CC).
Material and methods: Thirty-four patients who were operated on for UPSC and CC carcinoma at the İzmir Tepecik Re-
search and Teaching Hospital, between January 1983 and December 2014, were included. Patients were evaluated for the 
following factors: age, gravidity, parity, preoperative CA-125, tumor size, myometrial and lymphovascular invasion, lymph 
node tumor metastasis, presence of atypical cells in peritoneal cytology, pathology results, operation types, whether or 
not they received postoperative adjuvant therapy, prognosis, and death rate.
Results: The stage of the disease was the main factor affecting disease-free and the overall survival. Cisplatin-based 
chemotherapy was partially effective in patients with postoperative recurrence, while postoperative adjuvant radiotherapy 
proved to be more effective in preventing relapse.
Conclusion: The studied parameters generally were concordant with the literature but, due to the relatively small sample 
size, more comprehensive and multicenter studies are needed to generate valid results.
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INTRODUCTION
Endometrial cancer is the most common malignancy of 
the female genital tract. Understanding the management 
strategies for this cancer is important to identify high-risk 
patients and reduce the risks associated with cancer and 
early diagnosis. Uterine serous papillary carcinoma (UPSC) 
and clear-cell carcinoma (CC), which tend to occur in older 
patients, are rare but very aggressive type II endometrial 
cancers. In 1983, Bokhman developed a hypothesis that 
there are two histological types of endometrial carcinoma 
and they have significantly different risk factors [1]. Type 1 
or endometrioid carcinomas are estrogen-dependent tu-
mors and they occur on the basis of hyperplasia. Type 2 
or non-endometrioid tumors are usually seen in older 
patients and are less differentiated and more aggressive. 
Type 2 tumors are independent of estrogen stimulation 
and do not have precursor lesions [2]. Type 2 cancers af-
fect only 10–20% of patients with endometrial cancer 
but are responsible for 50% of deaths from endometrial 
cancer. The most common subgroups of type 2 endome-
trial cancer are uterine papillary serous carcinoma and 
clear-cell carcinoma [3]. UPSC is the most common type 2 
histologically and accounts for 17–22% of all endometrial 
cancer cases [3, 4]. Endometrial CC is rare and constitutes 
1–6% of all endometrial cancer cases [3, 4]. Due to the 
increasing incidence of endometrial carcinomas, it would 
require serious studies to determine risk factors, screening 
methods for early diagnosis, the most effective treatment 
methods, as well as survival and disease prognosis. The aim 
of the study was to evaluate the clinical and pathological 
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sal bleeding was the most common complaint in both 
groups. One infertile patient was identified in each group. 
Mean parity distribution was between 0–6 (3.27 ± 1.61) and 
0–8 (3.33 ± 1.95) in patients with CC and UPSC, respectively. 
As far as internal diseases and other cancers were concerned, 
diabetes mellitus was detected in 10 (43.41%) and 3 (27.3%) 
patients from the UPSC and CC groups, respectively. Hyper-
tension was detected in 9 (39.04%) patients from the UPSC 
group and in 1 (9.1%) patient from the CC group. A history 
of breast cancer was identified in 2 subjects from the UPSC 
group. Demographic characteristics of the patients are sum-
marized in Table 1. 
features, treatment, and prognosis of serous papillary and 
clear-cell uterine cancers.
MATERIAL AND METHODS
Thirty-four patients who were operated on due to serous 
papillary or clear cell types of endometrial carcinoma at the 
İzmir Tepecik Research and Teaching Hospital, between Jan-
uary 1983 and December 2014, were included in the study. 
Clinical and pathological and surgical data were collected. 
All patients were evaluated for survival and disease-free 
survival. The following clinical data were collected from 
patient medical, surgical, pathological, and chemotherapy 
reports: demographic characteristics, presenting symptoms, 
serum CA-125 level, date and type of the surgical procedure, 
presence or absence of residual tumor after surgery, number 
of excised and positive lymph nodes, presence or absence 
of ascites, tumor pathological characteristics (grade and 
size), type of first-line chemotherapy, date of recurrence, 
treatment after recurrence, date of the last medical examina-
tion, and date of death. The revised 2009 FIGO (Federation 
of Gynecology and Obstetrics) staging system was used. The 
patients were classified as ‘not staged’ if only a total hyster-
ectomy with unilateral or bilateral salpingo-oophorectomy 
with or without omentectomy was performed. Complete 
staging was defined as pelvic washing, peritoneal biopsy, 
omentectomy, bilateral pelvic and para-aortic lymph node 
dissection with bilateral salpingo-oophorectomy, and total 
abdominal hysterectomy. Optimal debulking was defined as 
a procedure which left a maximum residual tumor of < 1 cm 
in diameter. The patients returned for a follow-up every three 
months for the first 2 years, every 6 months for the next 
3 years, and annually thereafter. Computed tomography or 
magnetic resonance imaging was performed annually. The 
survival analysis was based on the Kaplan-Meier method, 
and the results were compared using the log-rank test. 
Progression free survival (PFS) was defined as the time from 
the date of the primary surgery to detection of recurrence or 
the latest observation. OS was defined as the time from the 
date of primary surgery to death or the latest observation. 
The chi-square test and Student’s t test for unpaired data 
were used for statistical analyses. Cox regression analysis 
was used to determine factors affecting the survival, and the 
results are presented as hazard ratios (HRs), with 95% confi-
dence intervals (CIs). All statistical analyses were performed 
using Statistical Package for the Social Sciences (SPSS ver. 
11.5). The p-value of < 0.05 was considered as statistically 
significant.
RESULTS
Mean patient age was 59.9 years at diagnosis. Age 
distribution was between 40 and 74 years. Postmenopau-
Table 1. Demographic and morphological features
Serous 
papillary Clear cell
No (%) No (%)
Age (years)
< 40 – – 1 (9.1)
46–74 23 (100) 10 (90.9)
Parity
Nulliparity 1 (4.3) 1 (9.1)
Multiparity 22 (95.7) 10 (90.9)
Complaint 
Postmenopausal 
bleeding 22 (95.7) 8 (72.7)
Other 1 (4.3) 3 (27.3)
Diabetes mellitus 6 (26.1) 2 (18.2)
Hypertension 5 (21.7) – –
DM + HT 4 (17.3) 1 (9.1) 
Breast cancer 2 (8.3) – –
FIGO stage
IB 4 (17.4) 8 (72.7)
IC 8 (34.8) – –
IIA 1 (4.3) – –
IIB 3 (13.0) – –
IIIA 2 (8.7) 1 (9.1)
IIIC 5 (21.7) 2 (18.2)
Myometrial invasion
Yok – – – –
< ½ 7 (30.4) 9 (81.8)
> ½ 16 (69.6) 2 (18.2)
Lymphovascular invasion
(+) 8 (34.8) 2 (18.2)
(–) 15 (65.2) 9 (81.8)
Cervical involvement
(+) 7 (30.4) 3 (27.3)
(–) 16 (69.6) 8 (72.7)
Æ
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was 72.7 ± 52.8 months and 81.7 ± 40.4 months for UPSC 
and CC groups.
DISCUSSION
UPSC and CC are highly aggressive tumors, which are 
characterized independently of endometrial hyperplasia 
and hyperestrogenemia [5]. These two species are very likely 
to have extrauterine spread [6]. Even though the primary 
lesion is very small, early myometrial, lymphovascular, and 
abdominal lymph node invasion can be seen [7]. Average 
age of type 2 cancer-affected patients is very high. Banch-
er-Todesa et al., reported that mean age of patients with 
UPSC was 72.4 years [8], while Rosenberg et al., reported it to 
be 69 years [9]. Regardless, mean age of patients in our series 
was incompatible with the literature. In the UPSC group, 
10 patients aged 46–60 accounted for 43.5% and 13 pa-
tients aged > 61 accounted for 56.5% of the cases. In the CC 
group, there was 1 (9.09%) patient who was < 40 years old, 
4 (36.4%) patients aged between 46 and 60, and 6 (54.5%) 
patients aged > 61. In our study, mean age at diagnosis was 
59.9, which is almost 10 years earlier than the mean age 
reported in the literature.
Postmenopausal bleeding has been reported as the 
most common symptom in non-endometrioid cancer [10]. 
Postmenopausal bleeding was identified as the initial symp-
tom in 22 (95.7%) patients from the UPSC and 11 patients 
(72.7%) with from the CC groups in our study. In a study 
by Bancher-Todesca et al., postmenopausal bleeding was 
reported as the initial symptom in 20 out of 23 patients [8]. 
In our study, obesity, diabetes, and hypertension were not 
found to be associated with the development of non-en-
dometrioid types of disease. Breast cancer is another factor 
associated with endometrial cancer, and its prevalence in 
the general population is 12.2% [11]. In our study, only 
2 patients from the UPSC group (8.3%) had a history of 
breast cancer.
Endometrial cancer histological type is one of the 
most important factors influencing patient survival. In its 
annual report, FIGO presented five-year survival rates of 
83% for endometrioid histology, 62% for clear cell histol-
ogy, and 53% for serous cell tumors. It is described that 
even the five-year survival is 90% for stage I endometrioid 
histology, 85% for stage I clear cell histology, and 80% for 
stage I serous cell tumors [12, 13]. Data in our study are 
consistent with the general literature, but CC groups were 
found to have a worse prognosis. Endometrioid histology 
is observed in more early stages but type 2 tumors (serous 
papillary and clear cell) are often detected at an advanced 
stage [12]. Mendivil et al., reported that 84% of patients 
diagnosed with stage 1–2 for endometrioid histology and 
this rate is 62% for serous papillary tumors [14]. In our 
Sixteen patients had FIGO stage 1–2 and seven patients 
had FIGO stage 3 in the UPSC group. There were no patients 
with FIGO stage 2 in the CC group, but 8 patients had FIGO 
stage 1 and 3 patients had stage 3 disease in the clear cell 
group. The most common metastatic locations were lung 
metastases in both groups. The UPSC group had 2 (8.6%) 
patients with lung metastases, 1 (4.34%) with para-aortic 
metastasis, and 1 (4.34%) with liver and retroperitoneal 
metastasis. The CC group had 1 patient (9.09%) with stump 
metastases, and 1 patient (9.09%) with lung metastasis. The 
surgical stage and morphological characteristics of the pa-
tients are shown in Table 1.
Primary total abdominal hysterectomy and bilateral 
salpingo-oophorectomy, pelvic and para-aortic lymph node 
excision, and infracolic omentectomy were performed in 
all cases. All patients received external pelvic radiotherapy 
except for 1 patient in the serous papillary group and 2 pa-
tients in the clear cell group. Recurrence developed in 7 pa-
tients, so they received cisplatin (50 mg/m2) and doxorubicin 
(50 mg/m2) intravenously every 3 weeks. Mean survival rate 
Table 1. Demographic and morphological features (cont.)
Serous 
papillary Clear cell
No (%) No (%)
Adnexal metastasis
(+) 4 (17.4) – –
(–) 19 (82.6) 11 (100)
Peritoneal washings
Benign 23 (100) 9 (81.8)
Malign – – 2 (18.2)
Lymph node involvement
No 10 (43.5) 3 (27.3)
Pelvic 3 (13) 3 (27.3) 
Pelvic + paraaortic 10 (43.5) 5 (45.5)
Grade 
Uncertain 8 (34.8) 4 (36.4)
1 5 (21.7) – –
2 4 (17.4) 3 (27.3)
3 6 (26.1) 4 (36.4)
Adjuvant therapy
No 1 (4.34) 2 (18.1)
ERT 4 (17.3) 1 (9.9)
ERT + IRT 18 (78.2) 8 (72.7)
Radiochemotherapy 5 (21.7) 2 (18.1)
Survival (months)
OS 72.7 ± 52.8 81.7 ± 40.4
DFS 61.6 ± 56.4 72.8 ± 48.5
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study, 16 patients (69.5%) were diagnosed at stage 1–2 in 
the UPSC group, while 8 patients (72.7%) at stage 1 in the 
CC group. In contrast to the literature, type 2 tumors were 
observed at an early stage.
Myometrial invasion is one of the most important in-
dependent prognostic factors for endometrial cancer. In 
several studies, it was reported that superficial invasion 
was detected in 40–65%, deep invasion in 10–42%, and 
no invasion in 10–24% of the cases [15, 16]. In our study, 
all patients presented myometrial invasion. Although su-
perficial myometrial invasion was detected in 30.4% of the 
subjects, deep myometrial invasion was detected in 69.6% 
of the papillary histological cases. Superficial myometrial 
invasion was identified as 81.8%, and deep myometrial 
invasion as 18.2% in CC. When myometrial invasion was 
assessed independently of disease stage, it was found to 
have caused metastasis and reduced disease-free survival 
in type 2 tumors. In one study, the tumor recurrence rate 
was only 13% if the tumors were localized in the fundus, 
but 44% if the tumors were localized in the lower uterine 
segment or the cervix [17]. Cervical involvement was de-
tected in 30.4% of UPSC patients and 85.7% of them had 
stromal invasion. The cervical involvement rate was 27.3% 
in the CC group and 66.6% of them had stromal invasion. 
The analysis of disease-free survival and overall survival 
revealed that cervical invasion decreased the survival in 
both groups.
Lymphovascular invasion is a strong predictor of recur-
rence. It is independent of the histological grade or myo-
metrial invasion [18, 19]. The presence of vascular invasion 
causes lymph node metastasis [20]. In our research, lymph 
node metastases were detected in 56.5% of patients with 
lymphovascular invasion in the UPSC group and 72.8% of 
patients with lymphovascular invasion in the CC group. 
These findings are also supported by the study about lymph 
node metastases by Cheewakriangkra et al. [21]. Pelvic 
lymph node involvement was detected in 13% of 23 pa-
tients, pelvic-para-aortic lymph node involvement in 43.5% 
of the UPSC group. Eleven patients had 27.3% pelvic and 
45.5% pelvic-para-aortic lymph node involvement in the CC 
group. While all patients were evaluated without histology, 
pelvic metastases proportion was 17.64%, pelvic-para-aortic 
metastases proportion was 44.11%. In its annual report 
published in 2006, FIGO reported that the five-year survival 
rate of patients with stage 3c disease was 57.3% [12]. In our 
study, the average overall survival was 43 months in patients 
who had stage 3c disease in the UPSC and 96 months in 
the CC groups.
Type II endometrial carcinoma is very susceptible to 
extrauterine spread. Even if the primary lesion is localized 
in a very small space, lymph node involvement and distant 
metastases can be observed [7]. Thus, all type II endometrial 
carcinomas should be staged surgically. All patients in our 
study were subjected to surgical staging. Due to the fact 
that non-endometrioid tumors have a worse prognosis, 
all patients, including those in the early stages, should 
receive adjuvant treatment [22]. However, the efficacy of 
postoperative adjuvant chemotherapy in these patients 
remains controversial. Some authors have reported that 
cisplatin-based chemotherapy provides a cure for non-en-
dometrioid tumors but other authors have reported a rela-
tive resistance to chemotherapy [7, 23, 24]. Five (21.7%) 
patients with UPSC and 2 (18.1%) with CC received cisplatin 
and doxorubicin treatment as adjuvant chemotherapy, 
but complete response was not observed in either group. 
Although radiotherapy is a significant adjuvant treatment 
for endometrioid tumors, the use of adjuvant radiotherapy 
in non-endometrioid tumors is slightly different [25, 26]. 
Bancher-Todesca et al., reported that mean 5-year survival is 
30% in patients with UPSC who were only treated with radi-
otherapy [8]. On the other hand, Mallipeddi et al., informed 
about a 50% survival in 10 patients who were treated by 
total abdominal radiotherapy [27], but Frank et al., reported 
that that treatment has no benefit [28]. In our study, the 
adjuvant radiotherapy was applied to 3 of the 4 patients 
with stage 1b and grade 2 diseases and distant metastases 
did not occur. Three patients with stage 1b grade 3 diseases 
received adjuvant radiotherapy and brachytherapy and 
one lung metastasis was observed within a month after 
the treatment.
CONCLUSIONS
The stage of disease was seen as the primary factor 
influencing disease-free and overall survival. In addition, 
non-endometrioid histology, increased grade, deep myome-
trial invasion, cervical stoma invasion, presence of malignant 
cells in cytology, adnexal involvement, lymphovascular inva-
sion, pelvic and/or para-aortic lymph node involvement, and 
tumor size were found to be effective in survival. We did not 
achieve statistically significant results to determine whether 
age, parity, and age at menarche and menopause constitute 
risk factors for endometrial cancer. Breast cancer was noted 
more frequently in the UPSC group, which was consistent 
with the literature. Cisplatin-based chemotherapy was par-
tially effective in patients with postoperative recurrence, 
but postoperative adjuvant radiotherapy was found to be 
more effective in preventing relapse. As a result, the his-
tory and findings of the patients were analyzed and then 
compared with the literature. The evaluated parameters 
were consistent with the literature. We conclude that there 
is a need for more extensive and multicenter studies to 
achieve valid results.
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